** Dimerix DXB.AX surges as much as 58.33% to A$0.760, highest since September 9, 2020
** Stock marks biggest intraday pct gain since October 5, 2023
** Biotech firm announces exclusive license agreement with Amicus Therapeutics FOLD.O to commercialise its Phase 3 drug candidate, DMX-200, in the U.S.
** Says DMX-200 currently being developed to treat focal segmental glomerulosclerosis kidney disease
** Stock sees busiest session since October 6, 2023, with more than 31 mln shares traded - 18.3x the 30-day avg
** Last up 50%, DXB more than doubles YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.